Efficacy, safety, and dose response of glycopyrronium administered by metered dose inhaler using co-suspension delivery technology in subjects with intermittent or mild-to-moderate persistent asthma: A randomized controlled trial

Article ID	Journal	Published Year	Pages	File Type
8819891	Respiratory Medicine	2018	41 Pages	PDF

Abstract

The results of this study suggest that GP MDI could offer an important treatment option for maintenance therapy of asthma, and warrants further investigation in Phase III clinical trials.

Keywords

DPI ACQ-5 SABA MedDRA MDI PEFR ICS FDC FEV1 mITT LAMA TEAE SAL Asthma long-acting muscarinic antagonist Long-acting β2-agonist Short-acting β2-agonist modified intent-to-treat ECG electrocardiogram standard deviation COPD Chronic obstructive pulmonary disease Fixed dose combination forced expiratory volume in 1 s peak expiratory flow rate standard error Metered Dose Inhaler twice daily Medical Dictionary for Regulatory Activities LSM Salmeterol LABA adverse event treatment-emergent adverse event confidence interval Co-suspension delivery technology Least squares mean Dry powder inhaler BID Inhaled corticosteroid Glycopyrronium

Related Topics

Health Sciences Medicine and Dentistry Pulmonary and Respiratory Medicine

Efficacy, safety, and dose response of glycopyrronium administered by metered dose inhaler using co-suspension delivery technology in subjects with intermittent or mild-to-moderate persistent asthma: A randomized controlled trial

Authors

Edward Kerwin, Andrew Wachtel, Lawrence Sher, Jack Nyberg, Patrick Darken, Shahid Siddiqui, Elizabeth A. Duncan, Colin Reisner, Paul Dorinsky,